ANA 2022: Preventive Eptinezumab Tied to Downgrades in Migraine Diagnosis
Change in diagnostic classification for current headache diagnosis seen for 35.7 to 48 percent of eptinezumab-treated patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.